Common Stock
- Symbol
- CNTX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 8.01, 9.01 · 8-K
Context Therapeutics Inc.
CNTXNASDAQEQUITYCurrent
Regulation FD Disclosure · Other Events
Item 7.01. Regulation FD Disclosure. On November 10, 2026, Context Therapeutics Inc. (the "Company") issued a press release announcing its third quarter 2026 operating and financial results and providing updates on its pipeline progress. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.…
Press release in this filing
Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress →Recent company filings
Registered securities in this filing
Context Therapeutics Inc. · 8-K · Filed 2026-11-10
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On November 10, 2026, Context Therapeutics Inc. (the "Company") issued a press release announcing its third quarter 2026 operating and financial results and providing updates on its pipeline progress. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.
The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On November 10, 2026, the Company updated its corporate presentation (the "Corporate Presentation"). A copy of the Corporate Presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.